Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75
million new cases worldwide in 2015. The World Health Organization aims for a 90 …

An estimated 1.5–2 million new hepatitis C virus (HCV) infections occur globally each year.
Critical to the World Health Organization's (WHO) HCV elimination strategy is an 80 …

The role that broadly neutralizing antibodies (bNAbs) play in natural clearance of human
hepatitis C virus (HCV) infection and the underlying mechanisms remain unknown. Here, we …

The early appearance of broadly neutralizing antibodies (bNAbs) in serum is associated
with spontaneous hepatitis C virus (HCV) clearance, but to date, the majority of bNAbs have …

Introduction Early development of broadly neutralizing antibodies (bNAbs) targeting the
hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance …

Abstract Background Hepatitis C virus (HCV) genomic variability is a major challenge to the
generation of a prophylactic vaccine. We have previously shown that HCV specific T-cell …

A prophylactic hepatitis C virus (HCV) vaccine that elicits neutralizing antibodies could be
key to HCV eradication. However, the genetic and antigenic properties of HCV envelope …

In the 26 years since the discovery of Hepatitis C virus (HCV) a major global research effort
has illuminated many aspects of the viral life cycle, facilitating the development of targeted …

Objectives HIV prevalence among Cambodian female sex workers (FSW) is among the
highest in Southeast Asia. We describe HIV prevalence and associated risk exposures in …

Objective Developing a vaccine that is cross-reactive between HCV genotypes requires data
on T cell antigenic targets that extends beyond genotype-1. We characterised T cell immune …